Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Keros Therapeutics, Inc. (KROS) had Consolidated Net Income/Loss of $-7.28M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$14.26M |
|
$-7.28M |
|
-- |
|
$14.26M |
|
$29.65M |
|
$-15.38M |
|
$6.68M |
|
$-8.70M |
|
$-8.70M |
|
$-7.28M |
|
$-7.28M |
|
|
Consolidated Net Income/Loss |
$-7.28M |
$-7.28M |
|
$-15.38M |
|
$-14.99M |
|
40.62M |
|
40.62M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$719.31M |
|
$4.56M |
|
$23.48M |
|
$742.78M |
|
$24.09M |
|
-- |
|
$15.11M |
|
$39.20M |
|
$703.58M |
|
$703.58M |
|
$703.58M |
|
40.63M |
|
| Cash Flow Statement Financials | |
$134.80M |
|
$-1.42M |
|
$0.16M |
|
$561.38M |
|
$694.92M |
|
$133.54M |
|
$21.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
29.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-107.87% |
|
-107.87% |
|
-- |
|
-61.03% |
|
-51.04% |
|
$133.38M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
4.08 |
|
22.04 |
|
-1.03% |
|
-1.03% |
|
-0.98% |
|
-1.03% |
|
$17.32 |
|
$3.28 |
|
$3.32 |
|